ArticleNanomedicine (London, England)2017
Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.
Article in Nanomedicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 91 citations in OpenAlex.
- Multimodal evaluation of mannose engineered poly lactic glycolic acid nanoparticles with granulocyte colony stimulating factor focused delivery to bone marrow for neutropenia.Scientific reports · 2026Article
- Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment ofDrug delivery · 2023Article
- Recent progress in nanotechnology-based drug carriers for resveratrol delivery.Drug delivery · 2023Review
- Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment.ACS omega · 2023Review
- Article
- Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.International journal of nanomedicine · 2023Article
- Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections.Pharmaceutics · 2022Review
- Current Development of Nano-Drug Delivery to Target Macrophages.Biomedicines · 2022Review
- Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections.Drug delivery and translational research · 2022Article
- Thiolated Chitosan Microneedle Patch of Levosulpiride from Fabrication, Characterization to Bioavailability Enhancement Approach.Polymers · 2022Article
- Applications of mannose-binding lectins and mannan glycoconjugates in nanomedicine.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2022Review
- Article
- Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.PLoS neglected tropical diseases · 2021Article
- Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.Journal of nanobiotechnology · 2021Review
- Thiolated Chitosans: A Multi-talented Class of Polymers for Various Applications.Biomacromolecules · 2021Review
- Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases.Drug delivery and translational research · 2020Review
- Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis.Molecules (Basel, Switzerland) · 2020Review
- Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.Molecules (Basel, Switzerland) · 2020Article
- Nanoparticles: New agents toward treatment of leishmaniasis.Parasite epidemiology and control · 2020Review
- Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: AnFrontiers in chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
aimOur goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. MATERIALS &
methodsA mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities.
resultsMTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC
conclusionThese studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.